Phase 3 N=249 HEALEY ALS Platform Trial - Regimen G DNL343
Amyotrophic Lateral Sclerosis
Primary: Disease Progression as Assessed by the ALSFRS-R-Slope — -0.88; -0.84 Percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=302 Initiating Early Control of Migraine Pain and Associated Symptoms
Migraine
Primary: Percentage of Subjects Achieving Headache Pain Freedom at Hour 2 — 43; 22 Participants — p=0.002
Phase 3 N=581 A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 24 — 0.276; 0.240; 0.067; 0.240 Liter — p=<0.0001
Phase 3 N=353 A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0 to 3 Hours (AUC0-3) at Week 12 — 0.309; 0.109 Liter — p=<0.0001
Phase 3 N=17 PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
Asthma
Primary: Part 1: Change From Mannitol Baseline Forced Expiratory Volume in the First Second (FEV1) Area Under the Curve (AUC [0-60 Min]) Post-mannitol Challenge 1…
Phase 3 N=408 Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
Chronic Rhinosinusitis With Nasal Polyps
Primary: Change From Baseline in Total Nasal Polyp Score at Week 52 — -2.458; -0.380 Score — p=<.0001
Phase 3 N=10 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
Relapsing Multiple Sclerosis
Primary: Glial Activity Load on PET — 0.968; 0.799; 0.759 Z-score
Phase 3 N=40 The Effect of Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis
Osteoarthritis, Knee · Knee Pain
Primary: Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS) Score - Pain — 64.4; 62.5; 63.9; 13.2 score on a scale — p=0.594
Phase 3 N=1,143 Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring
Contraception
Primary: Contraceptive Efficacy Using the Pearl Index for All Subjects — 2.96 Number of pregnancies per 100 women mths
Phase 3 N=52 Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Genital Warts
Primary: Change in the Maximum Size of the Genital Wart Lesion Over the Trial Period (as Measured in mm) — 8; 6; 11; 7 Participants
Phase 3 N=6 Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury.
Spinal Cord Injury
Primary: Change in Trabecular Plate Width (Tb.PW) for Femur and Tibia at 4.5 Months — 1785.42; 1819.41; 1805.52; 1834.67 μm
Phase 3 N=783 Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Juvenile Idiopathic Arthritis
Primary: Composite of All Primary Endpoints — 13; 14; 41; 245 Participants — p=0.7357
Phase 3 N=180 Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Primary: Number of AEs, SAEs and AESIs — 3325; 107; 420 events
Phase 3 N=103 Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
ADHD · Attention Deficit Hyperactivity Disorder · ADHD - Combined Type
Primary: The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Attention Deficit Hyperactivity Disorder Rating Scale 5 (ADHD-RS-5)…
Phase 3 N=356,912 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Helminthiasis · Filariasis
Primary: Comparison of Arms - Benin — 322; 748; 11; 11 Participants